T cell immunostimulation by methyl inosine 5′-monophosphate: Application to infectious diseases

International Immunopharmacology

Volumn 3, Issue 8, 2003, Pages 1177-1186

  Signorelli, Kathy L ^a   Hadden, John W ^a  

^a Immuno Rx Inc   (United States)

Author keywords

Adjuvant; Cell mediated immunity; Immunostimulant; Thymomimetic; Vaccines

Indexed keywords

HEPATITIS B VACCINE; INFLUENZA VACCINE; METHYLINOSINE 5' MONOPHOSPHATE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY RESPONSE; BACTERIAL INFECTION; CELLULAR IMMUNITY; CONFERENCE PAPER; DRUG ACTIVITY; EXPERIMENTAL MODEL; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; POPULATION RISK; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS INFECTION;

EID: 0038307677     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00010-9     Document Type: Conference Paper

References (32)

1. World Health Organization: Global Mortality Statistics; 1999. www.who.int .
2. O'Hagan D.T., MacKichan M.L., Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. 15:2001;69-85.
3. Taylor C.E. Cytokines as adjuvants for vaccines: antigen-specific responses differ from polyclonal responses. Infect. Immun. 63:1995;3241-3244.
4. Babai I., Barenholz Y., Zakay-Rones Z., Greenbaum E., Samira S.et al. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine. 20:2001;505-515.
5. Watabe S., Xin K.Q., Ihata A., Lin L.J., Honsho A.et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine. 19:2001;4434-4444.
6. Looney R.J., Hasan M.S., Coffin D., Campbell D., Falsey A.R.et al. Hepatitis B immunization of healthy elderly adults: relationship between naïve CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J. Clin. Immunol. 21:2001;30-36.
7. Jha R., Lakhtakia S., Jaleel M.A., Narayan G., Hemlatha K. Granulocyte macrophage colony stimulating factor (GM-CSF) induced sero-protection in end stage renal failure patients to hepatitis B in vaccine non-responders. Ren. Fail. 23:2001;629-636.
8. Evans T.G., Schiff M., Graves B., Agosti J., Barritt M.L.et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin. Nephrol. 54:2001;138-142.
9. Hadden J.W. T-cell adjuvants. Int. J. Immunopharmacol. 16:1994;703-710.
10. Hadden J.W., Cornaglia-Ferraris P., Coffey R.G. Purine analogs as immunomodulators. Yamamura Y., Tada T. Progress in immunology. vol. V:1983;1393-1408 Academic Press, New York.
11. Natsumeda Y., Carr S.F. Human type I and II IMP dehydrogenases as drug targets. Ann. N.Y. Acad. Sci. 696:1993;88-93.
12. Hadden J.W., Hadden E.M., Coffey R.G. Isoprinosine augmentation of phytohemagglutinin-induced lymphocyte proliferation. Infect. Immun. 13:1976;382-387.
13. Hadden J.W. Thymomimetic drugs. Miescher P.A., Bolis L., Ghione M. Serono symposium on immunopharmacology. 1985;183-192 Raven Press, New York.
14. Sosa M., Saha A.R., Giner-Sorolla A., Hadden E.M., Hadden J.W. Immunopharmacological properties of inosine 5′-methyl monophosphate (MIMP). Ann. N.Y. Acad. Sci. 685:1993;458-463.
15. Hadden E.M., Wang Y., Sosa M., Coffey R.G., Giner-Sorolla A., Hadden J.W. Methyl Inosine Monophosphate (MIMP) augments T-lymphocyte mitogen responses and reverses various immunosuppressants. Int. J. Immunopharmacol. 17:1995;763-770.
16. Jimenez J.L., Punzon C., Navarro J., Munoz-Fernandez M.A., Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor kappa-B and nuclear factor of activated T cells activation. J. Pharmacol. Exp. Ther. 299:2001;753-759.
17. Sosa M., Saha A.R., Wang Y., Coto J., Giner-Sorolla A.et al. Potentiation of immune responses in mice by a new inosine derivative-methyl inosine monophosphate (MIMP). Int. J. Immunopharmacol. 14:1992;1259-1266.
18. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32:1998;155-172.
19. U.S. Patent No. 5614504.
20. Hadden J.W., Ongradi J., Specter S., Nelson R., Sosa M.et al. Methyl inosine monophosphate: a potential immunotherapeutic for early human immunodeficiency virus (HIV) infection. Int. J. Immunopharmacol. 14:1992;555-563.
21. Masihi K.N., Hadden J.W. Protection by methyl inosine monophosphate (MIMP) against aerosol influenza infection in mice. Int. Immunopharmacol. 2:2002;835-841.
22. Semenenko T.A., Mikhailov M., Hadden J.W. Enhancement of the immune response to hepatitis B surface antigen by methyl inosine monophosphate (MIMP). Masihi K.N. Immunotherapy of infections. 1994;115-121 Marcel Dekker, Berlin.
23. Levi R., Arnon R. synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine. 14:1996;85-92.
24. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices, February, 2001. Centers for Disease Control. Available at www.cdc.gov .
25. McClure KL. Influenza management: prevention, prophylaxis and treatment. American Society of Consultant Pharmacists Annual Meeting, 1999, conference summary. www.medscape.com .
26. Foster D.A., Talsma A., Furumoto-Dawson A., Ohmit S.E., Margulies J.R.et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am. J. Epidemiol. 136:1992;296-307.
27. Fedson D., Wajda A., Nicol J.P., Hammond G.W., Kaiser D.L., Roos L.L. Clinical effectiveness of influenza vaccination in Manitoba. JAMA. 270:1993;1956-1961.
28. Gross P., Hermogenes A., Sacks H., Lan J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons. Ann. Intern. Med. 123:1995;518-527.
29. Tasker S., Treanor J., Paxton W., Wallace M.R. Efficacy of influenza vaccination in HIV-infected persons: a randomized, double-blind placebo-controlled trial. Ann. Intern. Med. 131:1999;430-433.
30. Ginaldi L., De Martinis M., D'Ostillio A., Marini L., Loreto F.et al. The immune system in the elderly: II. Specific cellular immunity. Immunol. Res. 20:1999;109-115.
31. Whitman DB. The immunology of aging. Cambridge scientific abstracts. Available at www.csa.com .
32. Dong L., Mori I., Hossain M.J., Kimura Y. The senescence-accelerated mouse shows aging-related defects in cellular but not humoral immunity against influenza virus infection. J. Infect. Dis. 182:2000;391-396.